• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
 
Generic Name:  selumetinib
Date Designated:  05/10/2016
Orphan Designation:  Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.
Orphan Designation Status:  Designated/Withdrawn
FDA Orphan Approval Status:  Not FDA Approved for Orphan Indication
AstraZeneca Pharmaceuticals LP
1800 Concord Pike
P.O. Box 8355
Wilmington, Delaware 19803
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-